Company Analysis
Sign in

Damora Therapeutics, Inc. (DMRA)

Nasdaq: DMRA · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.5
◀ Past 5.3● Present 4.4▶ Future 6.7
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$210M-878.8%
Earnings per share$3.98+121.5%
Operating cash flow-$6.7M+63.9%
Cash$258M+1717.5%
Debtn/a
Shareholders’ equity$240M+1418.4%
Shares, diluted1,363,005+17.8%
Return on equity-87.3%
The recordfrom its filings
Filings in 202672
Newest filingNov 4 · 10-Q
Annual reportMar 19, 2026
Quarterly reportNov 4, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$300,000
Patents granted19
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$292MCash from operations -$59.1Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 4, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Sep 28, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 13, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 12, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton DMRA · research, not advice